Human Adrenocorticotropic Hormone Articles & Analysis
6 articles found
Introduction of TSH The Thyroid-Stimulating Hormone (TSH) protein is a crucial player in the regulation of thyroid function. In this blog post, we will explore the structure, function, and significance of TSH in maintaining a healthy thyroid. Structure of TSH Let's start by understanding the structure and function of TSH. TSH, also known as thyrotropin, is a glycoprotein hormone secreted by ...
The formation of 2,5-diketopiperazine (DKP) with a bicyclic structure is one of the most detrimental side reactions and degradation pathways affecting peptide synthesis. Despite its crucial role as a versatile building block in drug discovery, the formation of DKP reactions is highly undesirable in the production of peptide drugs. DKP formation can occur during the process of peptide drug ...
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results, as well as several corporate updates. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity, which opens doors for significant developments in biosimilars. Rani has been on the radar of major life science investors for years. The company caught ...
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut. Rani’s debut comes amidst a flurry of IPO activity in therapeutics. In 2020, 71 ...
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately $100 ...